The Regents of the University of California

United States of America

Back to Profile

Receive daily alerts for new
USPTO trademarks filed by this owner
1-100 of 8,048 for The Regents of the University of California Sort by
Query
Patent
World - WIPO
Aggregations Reset Report
Date
New (last 4 weeks) 48
2021 January (MTD) 27
2020 December 61
2020 November 60
2020 October 81
See more
IPC Class
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids 549
A61P 35/00 - Antineoplastic agents 232
A61K 38/00 - Medicinal preparations containing peptides 209
G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor 205
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum 186
See more
Found results for  patents
  1     2     3     ...     81        Next Page

1.

COMBINATION CANCER THERAPY AGENTS AND METHODS

      
Application Number US2020042453
Publication Number 2021/011844
Status In Force
Filing Date 2020-07-17
Publication Date 2021-01-21
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
  • Dubinett, Steven, S.
  • Liu, Bin
  • Lim, Raymond
  • Salehi-Rad, Ramin

Abstract

The present disclosure relates, in general, to methods for treating cancer comprising administering to a subject in need thereof an effective amount of CXCL9, CXCL10 or the combination, in combination with an immune checkpoint inhibitor. The CXCL9, CXCL10 or combination may be administered as a polypeptide, a polynucleotide or cells comprising a polynucleotide encoding CXCL9, CXCL10 or both. In one aspect, the treatment is amenable to patients with low or high mutational burden tumors.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

2.

PLANTS WITH ENHANCED RESISTANCE TO BACTERIAL PATHOGENS

      
Application Number US2020041531
Publication Number 2021/011348
Status In Force
Filing Date 2020-07-10
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Dahlbeck, Douglas
  • Ortega, Arturo
  • Schultink, Alex
  • Staskawicz, Brian, J.

Abstract

Bs5Bs5-likeBs5-like gene that are capable of conferring to plants comprising the alleles enhanced resistance to plant pathogens. The present invention further provides methods of using the plants and seeds in agricultural production to limit plant diseases caused by plant pathogens.

IPC Classes  ?

  • A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
  • C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

3.

NANOPOROUS LITHIUM VANADIUM FLUOROPHOSPHATE MATERIALS AND CATHODES FOR FAST CHARGING LI-ION BATTERIES

      
Application Number US2020042394
Publication Number 2021/011811
Status In Force
Filing Date 2020-07-16
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Tolbert, Sarah H.
  • Lin, Terri C.

Abstract

Nanoporous carbon coated lithium vanadium fluorophosphate materials and cathodes for fast charging li-ion batteries are described. Formation of the materials using polymer-templating is also described.

IPC Classes  ?

  • H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
  • H01M 4/04 - Processes of manufacture in general
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy

4.

COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS

      
Application Number US2020042542
Publication Number 2021/011875
Status In Force
Filing Date 2020-07-17
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Li, Huiying
  • Barnard, Emma

Abstract

Provided herein are methods and compositions for the treatment or prevention of a skin disease (e.g., acne) in a subject by administering to the subject a composition comprising iron or cobalt.

IPC Classes  ?

  • A61K 33/24 - Heavy metals; Compounds thereof
  • A61K 33/26 - Iron; Compounds thereof
  • A61K 35/741 - Probiotics
  • A61Q 19/08 - Anti-ageing preparations
  • A61P 17/10 - Anti-acne agents
  • A61K 8/99 - Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
  • A61K 8/19 - Cosmetics or similar toilet preparations characterised by the composition containing inorganic ingredients
  • A61K 2300/00 -

5.

LITHIUM-EXCESS TRANSITION-METAL-DEFICIENT SPINELS FOR FAST CHARGING/DISCHARGING LITHIUM-ION BATTERY MATERIALS

      
Application Number US2020041941
Publication Number 2021/011542
Status In Force
Filing Date 2020-07-14
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ceder, Gerbrand
  • Ji, Huiwen

Abstract

1+x2-y4-zzz where 0.2 ≤ x ≤ 1, 0.2 ≤ y ≤ 0.6, and 0 ≤ z ≤ 0.8; and TM is Mn, Ni, Co, Al, Sc, Ti, Zr, Mg, Nb, or a mixture thereof. The spinels achieve a higher gravimetric energy density than traditional spinels while still retaining high capacity at an extremely fast charging/discharging rate.

IPC Classes  ?

6.

BIOLOGICALLY INSPIRED SLEEP ALGORITHM FOR ARTIFICIAL NEURAL NETWORKS

      
Application Number US2020042686
Publication Number 2021/011931
Status In Force
Filing Date 2020-07-17
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Bazhenov, Maksim
  • Krishnan, Giri Prashanth
  • Tadros, Timothy

Abstract

Systems and methods for generating Artificial Neural Networks (ANNs) based on the principles of biological sleep are disclosed. Namely, the systems and methods can be configured to apply a sleep-like phase to ANNs which enables training to be generalized, performance to be improved, and catastrophic forgetting for sequential multi-task training to be prevented. Various implementations of these systems and methods can be configured to: (i) train an ANN using backpropagation algorithm, (ii) convert the architecture of the ANN to an equivalent Spiking Neural Network (SNN) and simulate a sleep phase in the SNN while using plasticity rules to modify synaptic weights, and (iii) convert the modified synaptic weights associated with the simulated sleep phase of the SNN back into the ANN. This transformation from ANN to SNN to ANN effectively emulates learning mechanisms actuated during biological sleep and, as such, overcomes limitations commonly associated with machine learning.

IPC Classes  ?

  • G06N 3/04 - Architecture, e.g. interconnection topology
  • G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means
  • G06N 3/08 - Learning methods

7.

ULTRAFAST TRACER IMAGING FOR POSITRON EMISSION TOMOGRAPHY

      
Application Number US2020042401
Publication Number 2021/011815
Status In Force
Filing Date 2020-07-16
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Zhang, Xuezhu
  • Qi, Jinyi
  • Cherry, Simon R.
  • Badawi, Ramsey D.
  • Wang, Guobao

Abstract

The disclosed embodiments relate to a system that performs ultra-fast tracer imaging on a subject using positron emission tomography. During operation, the system performs a high-temporal-resolution, total-body dynamic PET scan on the subject as an intravenously injected radioactive tracer propagates through the vascular system of the subject to produce PET projection data. Next, the system applies an image reconstruction technique to the PET projection data to produce subsecond temporal frames, which illustrate the dynamic propagation of the radioactive tracer through the vascular system of the subject. Finally, the system outputs the temporal frames through a display device.

IPC Classes  ?

  • A61B 6/03 - Computerised tomographs
  • A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • A61B 5/08 - Measuring devices for evaluating the respiratory organs
  • G01T 1/161 - Applications in the field of nuclear medicine, e.g. in vivo counting

8.

HUMAN MILK OLIGOSACCHARIDES FOR CONTROL OF DIETARY RESPONSE AND METABOLIC PHENOTYPE

      
Application Number US2020042630
Publication Number 2021/011905
Status In Force
Filing Date 2020-07-17
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Barile, Daniela
  • Lee, Sunhye
  • Raybould, Helen

Abstract

Provided herein are method for modulating dietary response in a subject. The methods include the administration of human milk oligosaccharides such as 2'-fucosyllactose to the subject. Dietary responses such as decreased adiposity, preservation of lean muscle mass, improved cognitive function, and reduced levels of inflammatory factors can be obtained in various populations, including those consuming high fat diets.

IPC Classes  ?

  • A23L 29/30 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing starch hydrolysates, e.g. dextrin
  • A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

9.

UNIVERSAL CHIMERIC ANTIGEN RECEPTORS AND METHODS FOR MAKING AND USING THEM

      
Application Number US2020042345
Publication Number 2021/011781
Status In Force
Filing Date 2020-07-16
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Wang, Yingxiao
  • Limsakul, Praopim
  • Wu, Yiqian

Abstract

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for engineering immune effector cells, e.g., T cells, NK cells, monocytes and/or macrophages to recognize and destroy a desired target cell, which can be a cancer cell, a dysfunctional cell, or an infected cell.

IPC Classes  ?

  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • C12N 15/09 - Recombinant DNA-technology
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

10.

CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER

      
Application Number US2020042573
Publication Number 2021/011885
Status In Force
Filing Date 2020-07-17
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Mcdermott, Martina, S.
  • O'Brien, Neil, A.

Abstract

The present disclosure provides antigen-binding proteins which bind to Claudin- 18.2 (CLDN18.2); bispecific antigen-binding proteins which bind to CLDN18.2 and a second antigen; and conjugates thereof. In various aspects, the antigen-binding proteins bind to Extracellular Loop 1 (ELI) of the extracellular domain of CLDN18.2. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

IPC Classes  ?

  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61P 35/00 - Antineoplastic agents
  • G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

11.

SYSTEMS AND METHODS FOR MEMORY SPECIFICITY WITH VIRTUAL REALITY

      
Application Number US2020041645
Publication Number 2021/011391
Status In Force
Filing Date 2020-07-10
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Craske, Michelle, G.
  • Treanor, Michael

Abstract

Systems and methods for virtualized treatments in accordance with embodiments of the invention are illustrated. One embodiment includes a method for providing a virtualized treatment experience. The method includes steps for generating a treatment sequence includes a plurality of treatment elements, generating a virtualized environment for the generated treatment sequence, providing a plurality of treatment elements within the virtualized environment, and providing a set of one or more prompts for at least one treatment element of the plurality of treatment elements.

IPC Classes  ?

  • A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
  • A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices
  • G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

12.

CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT

      
Application Number US2020041710
Publication Number 2021/011417
Status In Force
Filing Date 2020-07-10
Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Craik, Charles S.
  • Shokat, Kevan M.
  • Zhang, Ziyang
  • Rohweder, Peter J.

Abstract

The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.

IPC Classes  ?

  • C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
  • A61P 35/00 - Antineoplastic agents
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

13.

A WIRELESSLY POWERED FREQUENCY-SWEPT SPECTROSCOPY SENSOR

      
Application Number US2020040283
Publication Number 2021/007071
Status In Force
Filing Date 2020-06-30
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Babakhani, Aydin
  • Sun, Yuxiang

Abstract

Systems and methods in accordance with embodiments of the invention implement wirelessly powered frequency-swept spectroscopy sensors. One embodiment includes a first antenna configured to receive an incoming signal; an energy-harvesting circuit configured to produce DC energy; a power management unit; an on-chip signal source configured to use the incoming signal as a locking signal; and a second antenna configured to transmit back a signal locked to the frequency of the incoming signal. In a further embodiment, the wirelessly powered frequency-swept spectroscopy sensor includes a third antenna, where the third antenna is on-chip.

IPC Classes  ?

  • G01J 3/00 - Spectrometry; Spectrophotometry; Monochromators; Measuring colours
  • G01J 3/02 - Spectrometry; Spectrophotometry; Monochromators; Measuring colours - Details

14.

SYSTEMS AND METHODS FOR LONG-DISTANCE REMOTE SENSING WITH SUB-WAVELENGTH RESOLUTION USING A WIRELESSLY-POWERED SENSOR TAG ARRAY

      
Application Number US2020041007
Publication Number 2021/007210
Status In Force
Filing Date 2020-07-07
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Lyu, Hongming
  • Babakhani, Aydin

Abstract

Systems and methods for remote sensing are described. In an embodiment, an apparatus, includes: a radio frequency identification (RFID) tag; an electromagnetic transmitter configured to emit electromagnetic waves; an ultra-wideband (UWB) receiver; a computer system; where: the RFID tag is configured to be operated without a battery, and to be powered by the electromagnetic waves emitted by the electromagnetic transmitter; where the RFID tag is configured to send out UWB impulses based on an amount of electromagnetic power received from the electromagnetic transmitter, such that a repetition rate of the UWB impulses varies with the amount of electromagnetic power received from the electromagnetic transmitter

IPC Classes  ?

  • H04Q 5/22 - Selecting arrangements wherein two or more subscriber stations are connected by the same line to the exchange with indirect connection, i.e. through subordinate switching centre the subordinate centre not permitting interconnection of subscribers connected thereto

15.

METHODS FOR IMPROVED REGENERATION OF TRANSGENIC PLANTS USING GROWTH-REGULATING FACTOR (GRF), GRF-INTERACTING FACTOR (GIF), OR CHIMERIC GRF-GIF GENES AND PROTEINS

      
Application Number US2020041135
Publication Number 2021/007284
Status In Force
Filing Date 2020-07-08
Publication Date 2021-01-14
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (Argentina)
Inventor
  • Dubcovsky, Jorge
  • Debernardi, Juan Manuel
  • Tricoli, David
  • Palatnik, Javier

Abstract

GRFGRFGIFGRFGIFGIF genes and proteins. The disclosure also provides plants with an improved regeneration efficiency that are produced by the disclosed methods, methods of reducing the use of exogenous cytokinins in the regeneration of plants, and methods of improving the regeneration efficiency of plants.

IPC Classes  ?

  • C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

16.

LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME

      
Application Number US2020041277
Publication Number 2021/007367
Status In Force
Filing Date 2020-07-08
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Gartner, Zev
  • Patterson, David
  • Chow, Eric
  • Weber, Robert
  • Mcginnis, Christopher

Abstract

The disclosure generally relates to methods and applications of single-cell barcoding and methods of nucleotide sequencing using composition comprising lipid-modified oligonucleotides.

IPC Classes  ?

  • C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen
  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
  • C12Q 1/6869 - Methods for sequencing

17.

PULSED-COHERENT ELECTRONIC FRONT END FOR LIDAR AND RADAR DETECTION AND RANGING

      
Application Number US2020041443
Publication Number 2021/007454
Status In Force
Filing Date 2020-07-09
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Yang, Chihkong
  • Chen, Liyang

Abstract

Systems and methods for a light detection and ranging (lidar) system utilizing both coherent and pulsed detection for Time of Flight (ToF) measurement are disclosed. In one embodiment, a lidar system includes a reference clock providing a clock signal (CKref) with time period Tcik, an automatic gain control (AGC) loop that is triggered when a received signal RFin is greater than a threshold voltage Vth, a coherent detector measuring a fine ToF by detecting the phase difference (ΔΦ) between the clock signal (CKref) and the received signal (RFin), a pulse edge detector measuring a coarse ToF by detecting a falling edge (post-edge) of the received signal (RFin) and counting cycles N to estimate an arrival time of N x Tcik, and a combiner that calculates total ToF by combining output of the coherent detector and pulse edge detector using the equation.

IPC Classes  ?

  • G01S 17/10 - Systems determining position data of a target for measuring distance only using transmission of interrupted, pulse-modulated waves
  • G01S 17/32 - Systems determining position data of a target for measuring distance only using transmission of continuous waves, whether amplitude-, frequency-, or phase-modulated, or unmodulated
  • G01S 17/36 - Systems determining position data of a target for measuring distance only using transmission of continuous waves, whether amplitude-, frequency-, or phase-modulated, or unmodulated with phase comparison between the received signal and the contemporaneously transmitted signal

18.

SYNTHESIS OF EUROPIUM HALIDE PEROVSKITES IN SOLUTION PHASE

      
Application Number US2020040098
Publication Number 2021/007060
Status In Force
Filing Date 2020-06-29
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Yang, Peidong
  • Huang, Jianmei
  • Lei, Teng

Abstract

A solution phase synthesis process for preparing a rare earth perovskite, the process includes reacting an alkali metal material with a first surfactant ligand in the presence of a first solvent to obtain a first precursor complex solution; reacting a rare earth metal halide with a second surfactant ligand in the presence of a second solvent to obtain a second precursor complex solution; and reacting the first precursor complex solution with the second precursor complex solution in the presence of a third surfactant ligand and a third solvent to obtain the rare earth perovskite; wherein: the rare earth perovskite is in the form of nanocrystals; and the first solvent and third solvent comprise a non-coordinating solvent.

IPC Classes  ?

  • C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
  • C30B 29/12 - Halides
  • C09K 11/66 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing germanium, tin or lead
  • H01L 21/00 - Processes or apparatus specially adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof

19.

METHODS FOR SELECTIVELY MODIFYING AMINO ACIDS AND PRODUCTS MADE THEREBY

      
Application Number US2020040821
Publication Number 2021/007127
Status In Force
Filing Date 2020-07-03
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Chang, Michelle
  • Neugebauer, Monica E.
  • Benmaman, Jorge Marchand

Abstract

Disclosed herein are methods for the selective substitution of a hydrogen bonded to a carbon atom (e.g., a hydrogen of an aliphatic methylene group) of a compound, which comprise contacting the compound with a substituent in the presence of a BesD halogenase.

IPC Classes  ?

  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12P 13/06 - Alanine; Leucine; Isoleucine; Serine; Homoserine
  • C12P 13/08 - Lysine; Diaminopimelic acid; Threonine; Valine
  • C12P 13/10 - Citrulline; Arginine; Ornithine
  • C12P 21/00 - Preparation of peptides or proteins
  • C07K 14/36 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptomyces (G)
  • C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides

20.

WAVELENGTH SELECTIVE PHOSPHOR CONVERTING SYSTEM FOR LASER LIGHTING DEVICES

      
Application Number US2020040868
Publication Number 2021/007148
Status In Force
Filing Date 2020-07-06
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Reilly, Caroline E.
  • Lheureux, Guillaume
  • Weisbuch, Claude, C.A.

Abstract

2a255 5 ). The DBR has a structure with one or more repeating quarter-wavelength (λ /4) layers, while the FP resonator has a structure with one or more ?/4 layers surrounding a central half-wavelength (λ/2) cavity.

IPC Classes  ?

  • F21K 9/64 - Optical arrangements integrated in the light source, e.g. for improving the colour rendering index or the light extraction using wavelength conversion means distinct or spaced from the light-generating element, e.g. a remote phosphor layer
  • F21K 9/00 - Light sources using semiconductor devices as light-generating elements, e.g. using light-emitting diodes [LED] or lasers
  • F21K 9/60 - Optical arrangements integrated in the light source, e.g. for improving the colour rendering index or the light extraction
  • F21K 9/62 - Optical arrangements integrated in the light source, e.g. for improving the colour rendering index or the light extraction using mixing chambers, e.g. housings with reflective walls

21.

VARIANT TYPE V CRISPR/CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF

      
Application Number US2020040927
Publication Number 2021/007177
Status In Force
Filing Date 2020-07-06
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Doudna, Jennifer A.
  • Ma, Enbo
  • Liu, Junjie

Abstract

The present disclosure provides variant type V CRISPR/Cas effector polypeptides, nucleic acids encoding the variant polypeptides, and systems comprising the variant polypeptides or nucleic acids encoding same. The present disclosure provides methods for modifying a target nucleic acid, using a variant polypeptide of the present disclosure.

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

22.

AUTOMATED RAPID ON-SITE EVALUATION MACHINE AND STAIN

      
Application Number US2020041421
Publication Number 2021/007443
Status In Force
Filing Date 2020-07-09
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Mendoza, Alejandro S.
  • Afify, Alaa M.
  • Lucero, Steven A.

Abstract

An automated rapid on-site evaluation (ROSE) system for smearing, staining and capturing a digital image of a biological sample such as a fine needle aspiration (FNA) sample is presented. The system comprises a housing with a user interface monitor or screen, a smearing system, a staining system, and an image capture system. The housing can further include a receiver for a biological sample that can direct the sample to a sample slide. The smearing system is configured to smear the sample on the sample slide. The staining system is configured to stain the sample. The image capture system is configured to capture a magnified image of the sample and store the digital image in the housing or remotely. The digital images may be available immediately for local or off-site review. The wait time between staining the sample and image capture can be less than 60 seconds.

IPC Classes  ?

  • G01N 1/28 - Preparing specimens for investigation
  • G02B 21/34 - Microscope slides, e.g. mounting specimens on microscope slides
  • G06K 9/46 - Extraction of features or characteristics of the image
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

23.

SYSTEMS AND METHODS FOR PRODUCING TUNABLE NOISE DAMPING MATERIAL STRUCTURES

      
Application Number US2020041649
Publication Number 2021/007538
Status In Force
Filing Date 2020-07-10
Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Candler, Robert, N.
  • Hopkins, Jonathan
  • Kavehpour, Hossein, Pirouz
  • Eldredge, Jeffrey, D.

Abstract

A tunable material structure that intuitively reacts to incoming sound impulses in varying degrees such that the material structure responds in such a manner so as to reduce the amplitude of the incoming pulse by utilizing more than one shape altering orifice to generate vortexes in the downstream flow.

IPC Classes  ?

  • A61F 11/08 - Protective devices for the ears internal, e.g. earplugs

24.

MAGNETICALLY MODULATED COMPUTATIONAL CYTOMETER AND METHODS OF USE

      
Application Number US2020040664
Publication Number 2021/003369
Status In Force
Filing Date 2020-07-02
Publication Date 2021-01-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ozcan, Aydogan
  • Ray, Aniruddha
  • Zhang, Yibo
  • Di Carlo, Dino

Abstract

A computational cytometer operates using magnetically modulated lensless speckle imaging, which introduces oscillatory motion to magnetic bead-conjugated rare cells of interest through a periodic magnetic force and uses lensless time-resolved holographic speckle imaging to rapidly detect the target cells in three-dimensions (3D). Detection specificity is further enhanced through a deep learning-based classifier that is based on a densely connected pseudo-3D convolutional neural network (P3D CNN), which automatically detects rare cells of interest based on their spatio-temporal features under a controlled magnetic force. This compact, cost-effective and high-throughput computational cytometer can be used for rare cell detection and quantification in bodily fluids for a variety of biomedical applications.

IPC Classes  ?

  • G01N 15/10 - Investigating individual particles
  • B01D 35/06 - Filters making use of electricity or magnetism
  • B03C 1/005 - Pretreatment specially adapted for magnetic separation
  • B03C 1/02 - Magnetic separation acting directly on the substance being separated
  • B03C 1/32 - Magnetic separation acting on the medium containing the substance being separated, e.g. magneto-gravimetric-, magnetohydrostatic-, or magnetohydrodynamic separation

25.

ELECTROCHEMICAL CONVERSION

      
Application Number US2020026003
Publication Number 2021/002905
Status In Force
Filing Date 2020-03-31
Publication Date 2021-01-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Zhanaidarova, Almagul
  • Kubiak, Clifford, P.

Abstract

22 to CO. The application presents a class of electrodes, incorporating molecular catalysts in nanostructures, for robust and efficient electrochemical systems, specifically, selective and robust hybrid electrodes, by incorporating a rhenium (Re) catalyst into the structure of highly porous heterogeneous materials. These electrodes can be scaled up to desired manufacturing dimensions due to their robust nature and methods of preparation.

IPC Classes  ?

26.

QUADRATURE PHASE SHIFT KEYING QUADRATURE AMPLITUDE MODULATION TRANSMITTER

      
Application Number US2020038073
Publication Number 2021/003019
Status In Force
Filing Date 2020-06-17
Publication Date 2021-01-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Mohammadnezhad, Hossein
  • Wang, Huan
  • Heydari, Payam

Abstract

Aspects of quadrature phase shift keying for quadrature amplitude modulation are described. In some examples, quadrature phase shift keying signals are generated using quadrature phase shift keying modulators. The quadrature phase shift keying signals are combined in a combiner circuit to generate a quadrature amplitude modulation signal for wireless transmission.

IPC Classes  ?

  • H04L 27/00 - Modulated-carrier systems
  • H04L 27/32 - Carrier systems characterised by combinations of two or more of the types covered by groups , , , or
  • H04L 27/34 - Amplitude- and phase-modulated carrier systems, e.g. quadrature-amplitude modulated carrier systems
  • H04L 27/36 - Modulator circuits; Transmitter circuits

27.

IMMUNOTHERAPY TARGETING CELL SURFACE MARKER CD72 FOR THE TREATMENT OF B-CELL MALIGNANCIES

      
Application Number US2020040749
Publication Number 2021/003428
Status In Force
Filing Date 2020-07-02
Publication Date 2021-01-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Nix, Matthew
  • Wiita, Arun

Abstract

Provided herein are anti-CD72 nanobodies and methods of using such nanobodies for diagnostic and therapeutic purposes.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans

28.

ADDITIVE-FREE MANUFACTURING OF GEOMETRICALLY COMPLEX COMPONENTS FOR ELECTRICAL ENERGY STORAGE SYSTEMS

      
Application Number US2020029966
Publication Number 2020/263400
Status In Force
Filing Date 2020-04-24
Publication Date 2020-12-30
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • CALIFORNIA INSTITUTE OF TECHNOLOGY (USA)
Inventor
  • Schoenung, Julie M.
  • Acord, Katherine A.
  • Zheng, Baolong
  • Bertoli, Umberto Scipioni
  • Shapiro, Andrew A.
  • Chen, Qian Nataly
  • West, William C.

Abstract

In some embodiments, high-energy additive manufacturing (HE-AM) (e.g., directed energy deposition, powder injection, powder bed fusion, electron beam melting, solid-state, and ultrasonic) is used to overcome constraints of comparative EES fabrication techniques to produce chemical additive-free electrodes with complex, highly versatile designs for next generation EES. An exemplary rapid fabrication technique provides an approach for improving electrochemical performance while increasing efficiency and sustainability, reducing time to market, and lowering production costs. With this exemplary technique, which utilizes computer models for location specific layer-by-layer fabrication of three- dimensional parts (e.g., versatile design), a high degree of control over processing conditions may be achieved to enhance both the design and performance of EES systems.

IPC Classes  ?

  • B05D 3/06 - Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to radiation
  • C23C 24/08 - Coating starting from inorganic powder by application of heat or pressure and heat
  • C23C 26/00 - Coating not provided for in groups
  • C23C 28/02 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of metallic material

29.

INTEGRATED SYSTEM FOR MECHANICAL PROCESSING OF LIPOASPIRATE

      
Application Number US2020039187
Publication Number 2020/263858
Status In Force
Filing Date 2020-06-23
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Haun, Jered
  • Lombardo, Jeremy A.

Abstract

An integrated lipoaspirate processing system is disclosed for mechanically processing adipose tissue into a therapeutic material that, in some embodiments, may be directly injected into a subject. The system includes an emulsification device that is used to emulsify the lipoaspirate sample. The emulsified lipoaspirate is then filtered by a microfluidic filtration device. The filtrate of the microfluidic filtration device is then processed in a microfluidic dissociation device. The integrated platform or system helps standardize hydrodynamic processing of lipoaspirate by producing predictable and consistent shear forces and enabling automation in clinical settings. Progressive processing through multiple devices in series enables optimal recovery of regenerative cells while preventing clogging.

IPC Classes  ?

  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • A61K 35/35 - Fat tissue; Adipocytes; Stromal cells; Connective tissues 
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

30.

METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE

      
Application Number US2020039194
Publication Number 2020/263862
Status In Force
Filing Date 2020-06-23
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Zou, Yimin
  • Feng, Bo
  • Tian, Runyi
  • Freitas, Andiara

Abstract

Provided herein are methods and agents for modulating the signaling pathway and components thereof that are responsible for assembly and disassembly of synapses in neurons, including amyloid beta (Aβ) mediated synaptotoxicity and synapse loss. Also provided herein are methods for screening and identifying candidate agents capable of modulating synapse formation and (Aβ) mediated synaptotoxicity.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

31.

BCL11B OVEREXPRESSION TO ENHANCE HUMAN THYMOPOIESIS AND T CELL FUNCTION

      
Application Number US2020039414
Publication Number 2020/264019
Status In Force
Filing Date 2020-06-24
Publication Date 2020-12-30
Owner
  • CHILDREN'S HOSPITAL LOS ANGELES (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Parekh, Chintan
  • Crooks, Gay
  • Seet, Christopher
  • Montel-Hagen, Amelie

Abstract

BCL11BBCL11BBCL11B expression in the HSPCs, pluripotent stem cells, or mature T cells increases production and/or proliferation of T cells from the HSPCs and/or the pluripotent stem cells, and/or increases proliferation of the T cells.

IPC Classes  ?

32.

PI3KGAMMA INHIBITORS

      
Application Number US2020039563
Publication Number 2020/264120
Status In Force
Filing Date 2020-06-25
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Varner, Judith
  • Amaro, Rommie
  • Kaneda, Megan
  • Malmstrom, Robert
  • Feher, Victoria

Abstract

The present disclosure relates to ΡΙ3Κγ inhibitors and methods of their use.

IPC Classes  ?

  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

33.

REDUCED ORDER MODEL FOR COMPUTING BLOOD FLOW DYNAMICS

      
Application Number US2020039765
Publication Number 2020/264259
Status In Force
Filing Date 2020-06-26
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Mirramezani, Seyed, Mehran
  • Shadden, Shawn

Abstract

A computer- implemented method can include generating centerlines of a patient's cardiovascular network, determining geometric features of the cardiovascular network based on the centerlines and a three-dimensional (3D) computer model of the cardiovascular network, constructing a lumped parameter network (LPN) of resistors corresponding to the cardiovascular network, and solving a system of equations corresponding to flow and pressure for the LPN model.

IPC Classes  ?

  • A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure

34.

THZ IMPULSE AND FREQUENCY COMB GENERATION USING REVERSE RECOVERY OF PIN DIODE

      
Application Number US2020039800
Publication Number 2020/264279
Status In Force
Filing Date 2020-06-26
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Babakhani, Aydin
  • Razavian, Seyedmohammadreza

Abstract

Many embodiments provide a frequency comb receiver that includes a PIN diode, a THz pulse generator block that generates THz tones (LO) for coherent frequency comb detection, an on-chip antenna for broadband detection and a driver stage switched by a series of buffers, where a repetition rate of the LO tones are tunable over a range and determines a spacing between two adjacent tones in the corresponding frequency comb.

IPC Classes  ?

  • H01Q 3/26 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture
  • H01Q 3/38 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the phase by electrical means with variable phase-shifters the phase-shifters being digital
  • H01Q 13/08 - Radiating ends of two-conductor microwave transmission lines, e.g. of coaxial lines, of microstrip lines
  • H01Q 21/06 - Arrays of individually energised antenna units similarly polarised and spaced apart

35.

METHODS AND COMPOSITIONS FOR TREATING SMITH-MAGENIS SYNDROME

      
Application Number US2020039898
Publication Number 2020/264350
Status In Force
Filing Date 2020-06-26
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Zou, Yimin
  • Scott, John
  • Thakar, Sonal

Abstract

The present invention is based on the finding that subanesthetic doses of N-methyl-D-aspartate (NMDA) receptor antagonists alleviate social interaction deficits associated with behavioral disorders, such as Smith-Magenis Syndrome (SMS). The invention therefore provides methods and compositions for treating SMS. Also provided are methods of selecting NMDA receptor agonists useful in alleviating social interaction deficits associated with such behavioral disorders.

IPC Classes  ?

  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/04 - Centrally acting analgesics, e.g. opioids
  • A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups

36.

STRAIN ENGINEERING AND EPITAXIAL STABILIZATION OF HALIDE PEROVSKITES

      
Application Number US2020040083
Publication Number 2020/264483
Status In Force
Filing Date 2020-06-29
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Xu, Sheng
  • Chen, Yimu
  • Lei, Yusheng

Abstract

In accordance with a method of forming a halide perovskite thin film, a first halide perovskite material is chosen from which a halide perovskite thin film is to be formed. An epitaxial substrate formed from a second halide perovskite material is also chosen. The halide perovskite thin film is epitaxially formed on the substrate from the first halide perovskite material. The substrate is chosen such that the halide perovskite thin film formed on the substrate has a selected value of at least one property. The property is selected from the group including crystal structure stability, charge carrier mobility and band gap.

IPC Classes  ?

  • H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
  • H01L 51/54 - Selection of materials
  • H01L 51/56 - Processes or apparatus specially adapted for the manufacture or treatment of such devices or of parts thereof

37.

TRITERPENE PRODUCTION

      
Application Number US2020036014
Publication Number 2020/263524
Status In Force
Filing Date 2020-06-03
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Keasling, Jay D.
  • Liu, Yuzhong

Abstract

An engineered microbial cell expressing a β-amyrin synthase, a cytochrome P450 reductase, a cytochrome P450 C28 oxidase, a cytochrome P450 C16 oxidase and a cytochrome C23 oxidase is used to make quillaic acid from β-amyrin.

IPC Classes  ?

  • C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymes; General processes for the preparation of compounds or compositions by using microorganisms or enzymes
  • C12P 5/00 - Preparation of hydrocarbons

38.

SIRPalpha-SILENCED NATURAL KILLER (NK) CELLS

      
Application Number US2020039220
Publication Number 2020/263880
Status In Force
Filing Date 2020-06-24
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Deuse, Tobias

Abstract

The invention provides Natural Killer (NK) cells that have a reduced or ablated Signal Regulatory Protein Alpha (SIRPα -) function when compared to a NK cell having an unmodified SIRPα - function that effectively kills a population of cancer cells that express CD47.

IPC Classes  ?

  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • C12N 5/074 - Adult stem cells
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N 15/52 - Genes encoding for enzymes or proenzymes

39.

METHODS FOR PREPARATION OF ACTIVE SEPARASE

      
Application Number US2020039264
Publication Number 2020/263909
Status In Force
Filing Date 2020-06-24
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Rosen, Laura E.
  • Morgan, David O.

Abstract

Provided herein are polypeptide constructs containing a securin, e.g., a full-length securin or a truncated securin, fused to a separase. The polypeptide constructs may further contain linker peptides, protease recognition sites, and unfoldase recognition sites to facilitate expression and/or purification. Methods for obtaining the polypeptide constructs with active separase activity are also described, as well as methods for identify separase modulator compounds such as separase inhibitors.

IPC Classes  ?

  • C01N 33/78 -
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N 5/02 - Propagation of single cells or cells in suspension; Maintenance thereof; Culture media therefor
  • C12N 5/08 -

40.

SYSTEMS AND METHODS FOR CHARACTERIZING JOINT ATTENTION DURING REAL WORLD INTERACTION

      
Application Number US2020039536
Publication Number 2020/264101
Status In Force
Filing Date 2020-06-25
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Chukoskie, Leanne
  • Cosman, Pamela
  • Venuprasad, Pranav
  • Paul, Anurag
  • Dobhal, Tushar
  • Nguyen, Tu
  • Gilman, Andrew

Abstract

Systems, devices, and methods are disclosed for characterizing joint attention. A method includes dynamically obtaining video streams of participants; dynamically obtaining gaze streams; dynamically providing a cue to the participants to view the object; dynamically detecting a joint gaze based on the gaze streams focusing on the object over a time interval; and dynamically providing feedback based on detecting the joint gaze.

IPC Classes  ?

  • A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
  • G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

41.

COMPOSITIONS AND METHODS OF FABRICATION OF NEAR INFRARED DEVICES

      
Application Number US2020039963
Publication Number 2020/264404
Status In Force
Filing Date 2020-06-26
Publication Date 2020-12-30
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Bazan, Guillermo C.
  • Lee, Jaewon
  • Song, Seyeong
  • Zhu, Ziyue
  • Nguyen, Thuc-Quyen
  • Ko, Seo-Jin

Abstract

A composition of matter including a donor including a dithiophene unit combined with a non-fullerene acceptor. Further disclosed is a device comprising an active region including the composition of matter. Example devices include a solar cell or a photodetector.

IPC Classes  ?

  • C07D 495/04 - Ortho-condensed systems
  • C07D 498/04 - Ortho-condensed systems
  • H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation

42.

SYSTEMS AND METHODS FOR FABRICATING CONFORMAL MAGNETIC RESONANCE IMAGING (MRI) RECEIVE COILS

      
Application Number US2020038077
Publication Number 2020/257242
Status In Force
Filing Date 2020-06-17
Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Arias, Ana Claudia
  • Gopalan, Karthik
  • Zamarayeva, Alla Mykhaylivna
  • Liu, Michael Zhi-Hon
  • Lustig, Shimon Michael

Abstract

Methods for forming conformal magnetic resonance imaging (MRI) receive coil devices having at least one receive coil with at least one capacitor are provided and include providing a 3-dimensional (3D) mold structure matching a curvilinear shape of interest, and forming a receive coil pattern on an outer surface of the 3D mold structure. The forming of the receive coil pattern may include spraying and/or depositing a conductive material and a dielectric material on the outer surface of the mold structure to form the receive coil pattern. The forming a receive coil pattern may include forming the receive coil pattern on an outer surface of a flat substrate sheet, and vacuum forming an inner surface of the flat substrate sheet to the outer surface of the mold structure to form a shape-conforming substrate sheet. The shape-conforming substrate sheet may be removed from the mold and used in MRI studies.

IPC Classes  ?

  • G01R 33/34 - Constructional details, e.g. resonators
  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

43.

CRISPR-CAS3 FOR MAKING GENOMIC DELETIONS AND INDUCING RECOMBINATION

      
Application Number US2020038821
Publication Number 2020/257715
Status In Force
Filing Date 2020-06-19
Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Leon, Lina Maria
  • Csorgo, Balint
  • Bondy-Denomy, Joseph

Abstract

The present disclosure provides methods and compositions for generating deletions, inducing recombination, and for modulating gene expression in cells using type I CRISPR-Cas systems.

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 15/01 - Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
  • C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

44.

STABLE COLLOIDAL DRUG AGGREGATES AND METHODS OF MANUFACTURE AND USE THEREOF

      
Application Number CA2020050845
Publication Number 2020/252581
Status In Force
Filing Date 2020-06-18
Publication Date 2020-12-24
Owner
  • THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Shoichet, Molly S.
  • Ganesh, Ahil N.
  • Donders, Eric N.
  • Shoichet, Brian K.
  • Torosyan, Hayarpi

Abstract

The present application provides a colloid drug aggregate composition and methods of use and manufacture thereof. While the formation of colloidal aggregates leads to artifacts in early drug discovery, their composition makes them attractive as nanoparticle formulations for targeted drug delivery. The present application provides an acid-responsive composition comprising: a colloidal aggregate of one or more drugs and a stabilizing agent, wherein the colloidal aggregate disrupts, dissolves or disassembles when the acid-responsive composition is in an acid environment having a pH of less than 7.4. The colloidal aggregate of the composition will disassemble upon contact with acid or upon introduction to an acidic environment, such as is found in the endosomes of cells. This approach makes this composition an attractive vehicle for drug delivery to a target site in a subject or to cells.

IPC Classes  ?

  • A61K 9/10 - Dispersions; Emulsions
  • A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
  • A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
  • A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
  • C07D 233/62 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with triarylmethyl radicals attached to ring nitrogen atoms
  • C07D 239/94 - Nitrogen atoms
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

45.

MIXED-SIGNAL ACCELERATION OF DEEP NEURAL NETWORKS

      
Application Number US2020038551
Publication Number 2020/257531
Status In Force
Filing Date 2020-06-18
Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ghodrati, Soroush
  • Esmaeilzadeh, Hadi

Abstract

Disclosed are devices, systems and methods for accelerating vector-based computation. In one example aspect, an accelerator apparatus includes a plurality of mixed-signal units, each of which includes a first digital-to-analog convertor configured to convert a subset of digital-domain bits to a first analog-domain signal and a second digital-to-analog convertor configured to convert a subset of digital-domain bits to a second analog-domain signal. Each mixed-signal unit also includes a capacitor coupled to the digital-to-analog convertors to accumulate a result of a multiplication operation as an analog signal. The apparatus includes a circuitry coupled to the mixed-signal units to shift part of the analog signals of the plurality of mixed-signal units. The circuitry comprises an additional capacitor to store an analog-domain result for a multiply-accumulate operation. The apparatus also includes an analog-to-digital converter coupled to the circuitry to convert the analog-domain result into a digital-domain result.

IPC Classes  ?

  • H03M 1/12 - Analogue/digital converters
  • H03M 1/14 - Conversion in steps with each step involving the same or a different conversion means and delivering more than one bit
  • H03M 1/18 - Automatic control for modifying the range of signals the converter can handle, e.g. gain ranging
  • H03M 1/72 - Sequential conversion in series-connected stages

46.

APPLICATION OF ARTIFICIAL INTELLIGENCE ON DETECTING CANINE LEFT ATRIAL ENLARGEMENT ON THORACIC RADIOGRAPHS

      
Application Number US2020038654
Publication Number 2020/257592
Status In Force
Filing Date 2020-06-19
Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Li, Shen
  • Cheng, Hao
  • Wisner, Erik, R.
  • Wang, Zigui

Abstract

A computer-executed method implementing a deep learning technique is carried out to perform on canine thoracic radiographic images an automated diagnosis of left atrial enlargement as an early sign of myxomatous mitral valve insufficiency.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
  • A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
  • G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
  • G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
  • G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

47.

LIPID NANODISCS SOLUBILIZED THROUGH POLY(ACRYLIC ACID-CO-STYRENE) COPOLYMERS

      
Application Number US2020038714
Publication Number 2020/257637
Status In Force
Filing Date 2020-06-19
Publication Date 2020-12-24
Owner
  • THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • AARHUS UNIVERSITY (Denmark)
Inventor
  • Appel, Eric A.
  • Smith, Anton
  • Autzen, Henriette E.
  • Cheng, Yifan

Abstract

Provided herein are compositions including lipids and copolymers in the form of a nanodisc assembly. The subject copolymers include monomer units of styrene and monomer units selected from acrylic acid and an acrylic acid derivative. In certain cases, the copolymer is a copolymer of styrene and acrylic acid. Also provided herein, is an aqueous solution comprising the subject composition. Also provided herein, are methods for producing a nanodisc assembly, including incubation of a lipid and a subject copolymer. Further provided herein, are methods for solubilizing a membrane protein in an aqueous solution, wherein the method includes forming a nanodisc assembly of a lipid bilayer having one or more membrane proteins embedded therein, and a subject copolymer. Also provided are methods of solubilizing a hydrophobic constituent in an aqueous solution, including forming a nanodisc assembly of a lipid, a hydrophobic constituent, and a subject copolymer.

IPC Classes  ?

  • C08F 220/14 - Methyl esters
  • G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol

48.

RATCHET-BASED ION PUMPING MEMBRANE SYSTEMS

      
Application Number US2020038814
Publication Number 2020/257708
Status In Force
Filing Date 2020-06-19
Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ardo, Shane
  • Segev, Gideon
  • Toma, Francesca
  • Ager, Joel
  • Kautz, Rylan
  • Larson, David

Abstract

Described herein is an ion pump system implementing an electronic ratchet mechanism produced by modulating a spatially varying electric potential distribution that can result in a net ionic current and voltage. The ion pumping membrane system includes an ion-permeable layer integrated with ion-selective membranes. The electric potential distribution within the ion-permeable layer is modulated through external stimuli. When immersed in solution, ions within the ion-permeable layer experience a time varying, spatially asymmetric electric field distribution resulting in ratchet-driven direct ion pumping, which can be used in applications such as desalination.

IPC Classes  ?

  • H01J 49/06 - Electron- or ion-optical arrangements
  • H01J 49/22 - Electrostatic deflection
  • H01J 49/24 - Vacuum systems, e.g. maintaining desired pressures

49.

SYSTEMS AND METHODS FOR MACHINE LEARNING-BASED IDENTIFICATION OF ACUTE KIDNEY INJURY IN TRAUMA SURGERY AND BURNED PATIENTS

      
Application Number US2020036170
Publication Number 2020/251833
Status In Force
Filing Date 2020-06-04
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Rashidi, Hooman H.
  • Tran, Nam K.

Abstract

In some aspects, the disclosure is directed to methods and systems for machine learning-based identification of acute kidney injury in trauma surgery and burned patients. A set of biomarker and vital sign measurements of a population with a known clinical diagnosis may be collected and normalized. A first subset of the modified set of biomarker and vital sign measurements may be used to train a neural network, and a second subset of the modified set of biomarker and vital sign measurements may be used for validation.

IPC Classes  ?

  • G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

50.

METHODS OF TREATING BILE ACID DIARRHEA

      
Application Number US2020036683
Publication Number 2020/251906
Status In Force
Filing Date 2020-06-08
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Verkman, Alan S.

Abstract

The disclosure is directed to methods of treating bile acid diarrhea by administering a CFTR chloride channel inhibitor (CFTR-CCI). The CFTR chloride channel inhibitor can be benzopyrimido-pyrrolo-oxazine-dione-CFTR-CCI (e.g., BPO-27), a PPQ-CFTR-CCI, a thiazolidinone-CFTR-CCI, or a glycine hydra-zide-CFTR-CCI.

IPC Classes  ?

  • A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 1/12 - Antidiarrhoeals

51.

STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF

      
Application Number US2020036845
Publication Number 2020/251953
Status In Force
Filing Date 2020-06-09
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Seiple, Ian, B.
  • Li, Qi
  • Fraser, James, S.
  • Pellegrino, Jenna

Abstract

inter aliainter alia, are streptogramin compounds, compositions, and methods of use thereof. A method of treating an infectious disease, the method including administering to a subject in need thereof an effective amount of a compound described herein.

IPC Classes  ?

  • A61K 31/33 - Heterocyclic compounds
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61P 31/04 - Antibacterial agents
  • C07D 215/34 - Carbamates
  • C07D 498/00 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D 499/40 - Amides; Hydrazides; Azides

52.

DE-IDENTIFICATION OF ELECTRONIC RECORDS

      
Application Number US2020036849
Publication Number 2020/251956
Status In Force
Filing Date 2020-06-09
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Norgeot, Beau
  • Butte, Atul
  • Schenk, Gundolf
  • Rutenberg, Eugenia

Abstract

A system is provided for de-identifying electronic records. The system may be configured to tokenize an electronic record to produce a plurality of tokens including a first token. The system may determine whether the first token is part of one of a plurality of expressions known to include protected health information. In response to determining that the first token is not part of any one of the plurality of expressions, the system may determine, based on a blacklist of tokens known to include protected health information, whether the first token includes protected health information. In response to determining that the first token includes protected health information, the system may generate a de-identified electronic record by replacing the first token with a second token obfuscating the protected health information. Related methods and computer program products are also provided.

IPC Classes  ?

  • H04L 29/06 - Communication control; Communication processing characterised by a protocol

53.

ENGINEERED OFF-THE-SHELF IMMUNE CELLS AND METHODS OF USE THEREOF

      
Application Number US2020037486
Publication Number 2020/252303
Status In Force
Filing Date 2020-06-12
Publication Date 2020-12-17
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • UNIVERSITY OF SOUTHERN CALIFORNIA (USA)
Inventor
  • Yang, Lili
  • Wang, Pin
  • Kim, Yu Jeong
  • Yu, Jiaji
  • Li, Yanruide

Abstract

Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered immune cells. Certain embodiments of the disclosure include compositions, cells, and methods related to engineered invariant natural killer T (iNKT) cells for off-the-shelf use for clinical therapy. The iNKT cells may be produced from hematopoietic stem progenitor cells and may be suitable for allogeneic cellular therapy because they are HLA negative. In some aspects, the cells have imaging and suicide targeting capabilities.

IPC Classes  ?

  • A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

54.

MODULATING ELECTRON TRANSFER KINETICS IN E-DNA-TYPE SENSORS

      
Application Number US2020037612
Publication Number 2020/252401
Status In Force
Filing Date 2020-06-12
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Plaxco, Kevin
  • Arroyo Curras, Netzahualcoyotl
  • Idili, Andrea

Abstract

in vivoin vivo sensor use with multiple measurements of analyte concentration per minute in flowing blood is demonstrated.

IPC Classes  ?

  • C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase

55.

NEW THERAPEUTIC APPROACH TO LUNG DISEASE

      
Application Number US2020037569
Publication Number 2020/252368
Status In Force
Filing Date 2020-06-12
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Sun, Xin
  • Xu, Jinhao

Abstract

The present disclosure provides a novel animal model of NEHI, and method of preventing and/or treating a pulmonary disease, particularly the lung-based complications in NEHI, such as pulmonary edema, by targeting the PNEC product, such as the CGRP signaling. Also disclosed is the pharmaceutical composition for preventing and/or treating a pulmonary edema and/or other pulmonary disease, particularly, NEHI, comprising one or more CGRP signaling antagonist and/or inhibitor of the present disclosure.

IPC Classes  ?

  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

56.

IMPROVEMENTS IN AND RELATING TO THE MONITORING OF CELL EXPANSION

      
Application Number EP2020065927
Publication Number 2020/249544
Status In Force
Filing Date 2020-06-09
Publication Date 2020-12-17
Owner
  • GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD (United Kingdom)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Goodwin, Paul, C
  • Bowles, Paul, Anthony
  • Iyer, Rohin
  • Gratch, Yarden
  • Mccartney, Mitch, M
  • Yamaguchi, Mei, S
  • Davis, Cristina, E

Abstract

Disclosed is a method for monitoring cell density during cell expansion resulting from a cell culture process in a bioreactor comprising the steps of: a) cultivating cells in a bioreactor culture chamber according to a cell culture process having cell culture parameters; b) during said process, introducing cell culture fluid inputs and generating waste materials; c) determining the intensity of volatile organic compounds (VOCs) and their chemical species in the waste materials; and d) estimating the density or population of cells in the bioreactor based on said determination.

IPC Classes  ?

  • C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

57.

COMPOSITIONS AND METHODS FOR MODULATING COGNITIVE BEHAVIOR

      
Application Number US2020035539
Publication Number 2020/251794
Status In Force
Filing Date 2020-06-01
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Hsiao, Elaine Y.
  • Olson, Christine
  • Iniguez, Alonso

Abstract

The present disclosure provides methods of treating hypoxia-induced cognitive impairment. Also disclosed are microbiome modulators, such as ketogenic-diet-suppressed bacterial species or antibiotics effective against a ketogenic-diet-boosted bacterial species, for use in treatment of cognitive impairment. The disclosure also provides methods of selecting a subject having hypoxia-induced cognitive impairment and methods of obtaining a prognostic indicator of hypoxia-induced cognitive impairment in a subject who receives a dosage of a microbiome modulator.

IPC Classes  ?

  • C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

58.

OSTEOINDUCTIVE MODIFIED GELATIN HYDROGELS AND METHODS OF MAKING AND USING THE SAME

      
Application Number US2020037381
Publication Number 2020/252230
Status In Force
Filing Date 2020-06-12
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Annabi, Nasim
  • Sani, Ehsan Shirzaei

Abstract

The present invention relates in part to a hydrogel composition and a method of fabricating the hydrogel composition comprising the steps of providing a solution comprising a polymer comprising crosslinkable groups; providing a solution comprising a crosslinking agent; mixing the solution comprising a polymer comprising crosslinkable groups and the solution comprising the crosslinking agent to form a combined solution; and crosslinking the combined solution. The invention also relates in part to a methods of treatment using the hydrogel composition.

IPC Classes  ?

  • A61C 13/00 - Dental prostheses; Making same
  • A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
  • A61L 27/52 - Hydrogels or hydrocolloids

59.

DNA CONSTRUCT FOR TARGETING THERAPEUTIC MOLECULES TO DISEASED TISSUE BY IMMUNE CELLS

      
Application Number US2020037462
Publication Number 2020/252282
Status In Force
Filing Date 2020-06-12
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Tidball, James G.
  • Wehling-Henricks, Michelle
  • Welc, Steven

Abstract

Provided herein are polynucleotide constructs comprising a CD11b promoter operably linked to a nucleic acid encoding one or more therapeutic polypeptides, to vectors, cells, and/or compositions comprising the same, and to methods of their use.

IPC Classes  ?

60.

ANTISENSE RNA EDITING OLIGONUCLEOTIDES COMPRISING CYTIDINE ANALOGS

      
Application Number US2020037580
Publication Number 2020/252376
Status In Force
Filing Date 2020-06-12
Publication Date 2020-12-17
Owner
  • PROQR THERAPEUTICS II B.V. (Netherlands)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Turunen, Janne, Juha
  • Fiet, Lenka, Van Sint
  • Kemmel, Cherie, Paige
  • Beal, Peter
  • Doherty, Erin, E.

Abstract

The invention relates to single-stranded RNA editing antisense oligonucleotides (AO Ns) for binding to a target RNA molecule for deaminating at least one target adenosine present in the target RNA molecule and recruiting, in a cell, preferably a human cell, an ADAR2 enzyme, to deaminate the at least one target adenosine in the target RNA molecule. The AON according to the invention comprises a cytidine analog at the position opposite the target adenosine, wherein the cytidine analog serves as an H-bond donor at the N3 site, for more efficient RNA editing.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine

61.

METHODS AND COMPOSITIONS FOR DETERMINATION LIVER FIBROSIS

      
Application Number US2020037638
Publication Number 2020/252413
Status In Force
Filing Date 2020-06-13
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Dennis, Edward, A.
  • Loomba, Rohit

Abstract

The disclosure provides methods for determining liver fibrosis development, risk and prognosis. The method includes measuring in a biological sample, one or more eicosanoids such as 5-HETE, 7,17-DHDPA, arachidonic acid, EPA, 16-HDOHE and 9-HODE using gas or liquid chromatography in combination with mass spectrometry. Methods of determining an improvement in hepatic collagen content are also described.

IPC Classes  ?

  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C07K 14/10 - Hepatitis A virus
  • G01N 33/576 - Immunoassay; Biospecific binding assay; Materials therefor for hepatitis

62.

DEEP LEARNING OF BIOMIMETIC SENSORIMOTOR CONTROL FOR BIOMECHANICAL MODEL ANIMATION

      
Application Number US2020037811
Publication Number 2020/252484
Status In Force
Filing Date 2020-06-15
Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Terzopoulos, Demetri
  • Nakada, Masaki

Abstract

Systems and methods for training and implementing a sensorimotor control framework in accordance with embodiments of the invention are illustrated. One embodiment includes a method for operating a sensorimotor control framework. The method includes steps for determining a current state of a musculoskeletal model, determining a desired state of the musculoskeletal model, computing a set of muscle activations, based on a difference between the current and desired states, and driving a musculoskeletal model based on the computed muscle activations.

IPC Classes  ?

  • G06T 13/20 - 3D [Three Dimensional] animation
  • G06N 20/00 - Machine learning
  • G06T 13/40 - 3D [Three Dimensional] animation of characters, e.g. humans, animals or virtual beings
  • G06T 17/00 - 3D modelling for computer graphics
  • G06T 19/00 - Manipulating 3D models or images for computer graphics

63.

CONVOLUTIONAL PRECODING AND DECODING OF POLAR CODES

      
Application Number US2020035936
Publication Number 2020/247508
Status In Force
Filing Date 2020-06-03
Publication Date 2020-12-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Fazeli Chaghooshi, Arman
  • Vardy, Alexander
  • Yao, Hanwen

Abstract

Devices, systems and methods for convolutional precoding and decoding of polar codes are disclosed. An example method for error correction in a data processing system includes receiving a noisy codeword, the codeword having been generated based on an outer stream decodable code and an inner polar code and provided to a communication channel or a storage channel prior to reception by the decoder, the stream decodable code characterized by a trellis, and performing, based on the trellis, a list-decoding operation on the noisy codeword vector to generate a plurality of information symbols, the list-decoding operation being configured to traverse through a plurality of states at one or more stages of a plurality of decoding stages.

IPC Classes  ?

  • H04L 1/00 - Arrangements for detecting or preventing errors in the information received
  • H03M 13/29 - Coding, decoding or code conversion, for error detection or error correction; Coding theory basic assumptions; Coding bounds; Error probability evaluation methods; Channel models; Simulation or testing of codes combining two or more codes or code structures, e.g. product codes, generalised product codes, concatenated codes, inner and outer codes

64.

DIBORONIC ACID COMPOUNDS AND METHODS OF MAKING AND USING THEREOF

      
Application Number US2020036167
Publication Number 2020/247662
Status In Force
Filing Date 2020-06-04
Publication Date 2020-12-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Wang, Bing
  • Chou, Kuang-Hua
  • Bazan, Guillermo C.
  • Pennathur, Sumita

Abstract

Disclosed are diboronic acid compounds and diboronic acid compound-based sensors for glucose detection, as well as methods for glucose testing in a sample. The diboronic acid compounds allow for selective detection of glucose in the presence of interference sugars, long-term stability, and ease of preparation. Sensors containing the disclosed diboronic acid compounds allow for selective detection of glucose with improved stability at a low cost.

IPC Classes  ?

65.

GENERAL FORM OF THE TREE ALTERNATING OPTIMIZATION (TAO) FOR LEARNING DECISION TREES

      
Application Number US2020036696
Publication Number 2020/247949
Status In Force
Filing Date 2020-06-08
Publication Date 2020-12-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Carreira-Perpiñán, Miguel Á.

Abstract

A computer-implemented Tree Alternating Optimization (TAO) algorithm for learning decision trees to find an approximate minimizer of an objective function over the parameters of the bee. Generally, the method comprises inputting an initial decision tree and a training set of instances, processing the initial decision tree by partitioning nodes into sets of non-descendant nodes, processing the nodes in each set by updating the nodes' parameters at each iteration so that the objective function decreases monotonically, and pruning the free, which produces a final free of a size no larger than that of the initial free. TAO applies to many different types of loss functions, regularization terms and constraints, and types of models at both the decision nodes and the leaves, and makes it possible to learn better decision trees than with traditional algorithms, and to learn bees for problems where traditional algorithms do not apply.

IPC Classes  ?

  • G06N 99/00 - Subject matter not provided for in other groups of this subclass

66.

SYSTEMS COMPRISING SUBSTRATES AND METHODS OF USING THE SAME FOR DETECTION OF PANCREATIC CANCERS

      
Application Number US2020036702
Publication Number 2020/247952
Status In Force
Filing Date 2020-06-08
Publication Date 2020-12-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Craik, Charles, S.
  • Ivry, Sam, L.

Abstract

Diagnostic platforms for the detection of mucinous and high grade cysts in the pancreas of subjects are provided. The disclosure provides a system comprising enzyme specific substrate, that are specific for detection and/or quantificiation of serine protease TPP-1, the value of which corresponding to a determination of whether a mucinous cyst in the pancreas is malignant or benign. The disclosure also provides for a two-step method, in which a sample from a pancreatic cyst is determined mucinous by detection and/or quantification of aspartyl protease expression, and then the same cyst is determined high grade dysplasia or malignant by detection and/or quantification of serine protease expression.

IPC Classes  ?

  • C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

67.

SYSTEM AND METHOD FOR REAL-TIME MULTICOLOR SHORTWAVE INFRARED FLUORESCENCE IMAGING

      
Application Number EP2020065753
Publication Number 2020/245446
Status In Force
Filing Date 2020-06-07
Publication Date 2020-12-10
Owner
  • HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (Germany)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Bruns, Oliver
  • Lingg, Jakob
  • Warmer, Martin
  • Ramakrishnan, Shyam S.
  • Saccomano, Mara
  • Sletten, Ellen
  • Cosco, Emily

Abstract

The present invention relates to systems, methods and fluorophores for real-time multicolor shortwave infrared fluorescence imaging. The systems and methods of the present invention further relate to real-time multi-color in vivo SWIR imaging systems employing high-power excitation sources in combination with state of the art InGaAs SWIR detectors and SWIR illuminated fluorophores.

IPC Classes  ?

68.

METHOD AND DEVICE FOR IMAGING FLUORESCENT PROTEINS IN NEAR- AND SHORT-WAVE INFRARED

      
Application Number EP2020065754
Publication Number 2020/245447
Status In Force
Filing Date 2020-06-07
Publication Date 2020-12-10
Owner
  • HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (Germany)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Bruns, Oliver
  • Lingg, Jakob
  • Fuenzalida-Werner, Juan-Pablo
  • Stiel, Andre
  • Warmer, Martin
  • Ramakrishnan, Shyam S.
  • Cosco, Emily
  • Sletten, Ellen

Abstract

The present invention relates to systems, methods and fluorescent polypeptide for real-time multicolor shortwave infrared fluorescence imaging. The systems and methods of the present invention further relate to real-time multi-color in vivo SWIR imaging systems employing high-power excitation sources in combination with state of the art InGaAs SWIR detectors and SWIR illuminated fluorescent polypeptide.

IPC Classes  ?

  • G01N 21/64 - Fluorescence; Phosphorescence
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

69.

PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME

      
Application Number US2020035643
Publication Number 2020/247336
Status In Force
Filing Date 2020-06-02
Publication Date 2020-12-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Lowry, William
  • Novitch, Bennett
  • Jung, Michael E.
  • Liu, Xiaoguang
  • Samarasinghe, Ranmal
  • Korsakova, Elena

Abstract

MECP2 MECP2 − mutations.

IPC Classes  ?

  • C12N 15/67 - General methods for enhancing the expression
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • A61K 31/428 - Thiazoles condensed with carbocyclic rings
  • A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
  • C07D 513/04 - Ortho-condensed systems

70.

PRODUCTION OF OLIGOSACCHARIDES FROM POLYSACCHARIDES

      
Application Number US2020035748
Publication Number 2020/247389
Status In Force
Filing Date 2020-06-02
Publication Date 2020-12-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Lebrilla, Carlito B.
  • German, Bruce
  • Amicucci, Matthew J.
  • Nandita, Eshani
  • Castillo, Juan
  • Mills, David A.

Abstract

Synthetic oligosaccharides and mixtures thereof which resemble polysaccharides produced by plants, yeast and other fungi, bacteria, and algae are described. The oligosaccharides and compositions provided herein are useful as synbiotics, prebiotics, immune modulators, digestion aids, and food additives.

IPC Classes  ?

  • A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
  • A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

71.

TREATMENT FOR AORTIC ANEURYSMS

      
Application Number US2020035860
Publication Number 2020/247453
Status In Force
Filing Date 2020-06-03
Publication Date 2020-12-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Boss, Gerard
  • Casteel, Darren
  • Rangaswami, Hema
  • Pilz, Renate

Abstract

Compositions and methods for treatment of aortic disease in a subject in need comprising an effective amount of cobinamide. Aortic diseases include for example aortic aneurysm, aortic dissection, or aortic dilation. Aortic disease can be caused for example by Marfan syndrome or oxidative stress.

IPC Classes  ?

  • C07F 15/06 - Cobalt compounds
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 38/08 - Peptides having 5 to 11 amino acids
  • A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

72.

SMALL MOLECULE INHIBITORS OF A PROTEIN COMPLEX

      
Application Number US2020036093
Publication Number 2020/247608
Status In Force
Filing Date 2020-06-04
Publication Date 2020-12-10
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • THE UNIVERSITY OF NEW MEXICO (USA)
Inventor
  • Gingras, Alexandre
  • Ginsberg, Mark
  • Ballatore, Carlo
  • Sklar, Larry
  • Francisco, Karol Rogelle Karagdag

Abstract

Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.

IPC Classes  ?

  • A61K 31/05 - Phenols
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
  • A61P 9/00 - Drugs for disorders of the cardiovascular system

73.

BIOFOULING RESISTANT COATINGS AND METHODS OF MAKING AND USING THE SAME

      
Application Number US2020036121
Publication Number 2020/247629
Status In Force
Filing Date 2020-06-04
Publication Date 2020-12-10
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • HYDROPHILIX, INC. (USA)
Inventor
  • Mcverry, Brian, T.
  • Rao, Ethan
  • Kaner, Richard, B.
  • He, Na

Abstract

Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.

IPC Classes  ?

  • A61L 31/08 - Materials for coatings
  • A61L 31/10 - Macromolecular materials
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61L 17/00 - Materials for surgical sutures or for ligaturing blood vessels
  • A61L 17/14 - Post-treatment to improve physical properties
  • A61L 27/34 - Macromolecular materials
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 29/08 - Materials for coatings
  • A61L 29/16 - Biologically active materials, e.g. therapeutic substances
  • A01N 33/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
  • A01N 33/12 - Quaternary ammonium compounds
  • A01N 33/20 - Nitro compounds containing oxygen or sulfur attached to the carbon skeleton containing the nitro group
  • A01N 41/06 - Sulfonic acid amides
  • C08F 220/38 - Esters containing sulfur
  • C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
  • C08J 7/04 - Coating
  • C09D 133/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur or oxygen atoms in addition to the carboxy oxygen
  • C09D 183/04 - Polysiloxanes
  • C09D 5/00 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes

74.

DIFFRACTIVE DEEP NEURAL NETWORKS WITH DIFFERENTIAL AND CLASS-SPECIFIC DETECTION

      
Application Number US2020036436
Publication Number 2020/247828
Status In Force
Filing Date 2020-06-05
Publication Date 2020-12-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ozcan, Aydogan
  • Rivenson, Yair
  • Li, Jingxi
  • Mengu, Deniz
  • Luo, Yi

Abstract

A diffractive optical neural network device includes a plurality of diffractive substrate layers arranged in an optical path. The substrate layers are formed with physical features across surfaces thereof that collectively define a trained mapping function between an optical input and an optical output. A plurality of groups of optical sensors are configured to sense and detect the optical output, wherein each group of optical sensors has at least one optical sensor configured to capture a positive signal from the optical output and at least one optical sensor configured to capture a negative signal from the optical output. Circuitry and/or computer software receives signals or data from the optical sensors and identifies a group of optical sensors in which a normalized differential signal calculated from the positive and negative optical sensors within each group is the largest or the smallest of among all the groups.

IPC Classes  ?

75.

ELECTRICAL STIFFNESS-BASED SENSOR

      
Application Number US2020036517
Publication Number 2020/247891
Status In Force
Filing Date 2020-06-06
Publication Date 2020-12-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Nguyen, Clark, T.-C.
  • Ozgurluk, Alper

Abstract

An on-chip strain measurement device that uses precision frequency measurements to precisely extract sub-nm displacements, allowing residual strain measurements in a given structural film. Strain-induced gap changes to resonance frequencies use differential strategies to remove bias uncertainty, allowing measurement of sub-nm displacements. Gap-dependent electrical stiffness is used to shift resonance frequencies as structural elements stretch or shrink to relieve strain. An output based on differential frequencies between two proximal structures with unequal stress arm lengths removes uncertainty on the initial gap spacing. The ability to precisely measure the frequency of the high-Q structures allows lifetime stress correction of micromechanical circuits, such as oscillators and filters.

IPC Classes  ?

  • G01C 19/56 - Turn-sensitive devices using vibrating masses, e.g. vibratory angular rate sensors based on Coriolis forces
  • G01P 15/125 - Measuring acceleration; Measuring deceleration; Measuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values by capacitive pick-up
  • G01C 19/5684 - Turn-sensitive devices using vibrating masses, e.g. vibratory angular rate sensors based on Coriolis forces using the phase shift of a vibration node or antinode of essentially two-dimensional vibrators, e.g. ring-shaped vibrators the devices involving a micromechanical structure
  • G01P 15/02 - Measuring acceleration; Measuring deceleration; Measuring shock, i.e. sudden change of acceleration by making use of inertia forces

76.

COMPUTATIONAL SENSING WITH A MULTIPLEXED FLOW ASSAYS FOR HIGH-SENSITIVITY ANALYTE QUANTIFICATION

      
Application Number US2020034349
Publication Number 2020/242993
Status In Force
Filing Date 2020-05-22
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ozcan, Aydogan
  • Joung, Hyou-Arm
  • Ballard, Zachary, S.
  • Garner, Omai
  • Di Carlo, Dino
  • Goncharov, Artem

Abstract

A system for detecting the presence of and/or quantifying the amount or concentration of one or more analytes in a sample includes a flow assay cartridge having a multiplexed sensing membrane that has immunoreaction or biological reaction spots of varying conditions spatially arranged across the surface of the membrane defining an optimized spot map. A reader device is provided that uses a camera to image the multiplexed sensing membrane. Image processing software obtains normalized pixel intensity values of the plurality of immunoreaction or biological reaction spots and which are used as inputs to one or more trained neural networks configured to generate one or more outputs that: (i) quantify the amount or concentration of the one or more analytes in the sample; and/or (ii) indicate the presence of the one or more analytes in the sample; and/or (ii) determines a diagnostic decision or classification of the sample.

IPC Classes  ?

  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

77.

METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS

      
Application Number US2020034484
Publication Number 2020/243060
Status In Force
Filing Date 2020-05-26
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Cai, Hua

Abstract

Disclosed herein are netrin-1 compounds and compositions thereof and methods of using thereof to treat, inhibit, or reduce conditions associated with or resulting from hyperlipidemia.

IPC Classes  ?

  • C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61P 3/06 - Antihyperlipidemics

78.

SYSTEMS AND METHODS FOR AUTOMATED IMAGE ANALYSIS

      
Application Number US2020034552
Publication Number 2020/243090
Status In Force
Filing Date 2020-05-26
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Arnold, Corey
  • Li, Jiayun
  • Speier, William
  • Li, Wenyuan

Abstract

In accordance with one aspect of the disclosure, an image analysis system is provided. The image analysis system includes at least one processor configured to access image tiles associated with a patient, each tile comprising a portion of a whole slide image, individually provide a first group of image tiles to a first trained model, receive a first set of feature objects from the first trained model, cluster feature objects from the first set of feature objects to form a number of clusters, calculate a number of attention scores based on the first set of feature objects, select a second group of tiles, individually provide the second group of image tiles to a second trained model, receive a second set of feature objects from the second trained model, generate a cancer grade indicator, and cause the cancer grade indicator to be output.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G06K 9/46 - Extraction of features or characteristics of the image
  • G06N 3/08 - Learning methods
  • G06T 7/00 - Image analysis

79.

METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS

      
Application Number US2020034954
Publication Number 2020/243329
Status In Force
Filing Date 2020-05-28
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Graeber, Thomas G.
  • Balanis, Nikolas G.
  • Sheu, Katherine M.
  • Witte, Owen N.
  • Esedebe, Favour
  • Park, Jung Wook

Abstract

The current disclosure provides for methods of identifying and treating small cell neuroendocrine (SCN) tumors and small-round-blue cell tumor (SRBCT). Aspects of the disclosure relate to a method comprising measuring the level of expression of one or more biomarkers from Tables 1-3 in a biological sample from a cancer patient. Further aspects relate to a method for treating small cell neuroendocrine (SCN) cancer or small-round-blue cell tumor (SRBCT) in a patient comprising administering a cancer treatment to the patient, wherein the cancer treatment is a treatment selected from Table 4A, 4B, or combinations of treatments from Table 4A and/or 4B.

IPC Classes  ?

  • A61P 35/00 - Antineoplastic agents
  • A61P 35/02 - Antineoplastic agents specific for leukemia
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

80.

METHODS AND COMPOSITIONS FOR TREATING EPILEPSY

      
Application Number US2020034981
Publication Number 2020/243349
Status In Force
Filing Date 2020-05-28
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Baraban, Scott, C.
  • Griffin, Aliesha, L.
  • Renslo, Adam, R.
  • Jaishankar, Priyadarshini

Abstract

Provided, inter alia, are methods and compositions for treating epilepsy. In one aspect, provided herein is a method of selecting a compound for treating epilepsy, said method includes, contacting a test compound with 5-hydroxytryptamine-2B receptor (5-HT2B), and measuring the 5-HT2B agonistic activity of the test compound. In another aspect, provided herein is a method of treating an epilepsy in a subject in need thereof. The method includes administering to said subject an effective amount of a 5-HT2B specific receptor agonist.

IPC Classes  ?

81.

ANTI-CRISPR INHIBITORS

      
Application Number US2020035403
Publication Number 2020/243627
Status In Force
Filing Date 2020-05-29
Publication Date 2020-12-03
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
Inventor
  • Bondy-Denomy, Joseph
  • Borges, Adair
  • Zhang, Jenny Yujie
  • Osuna, Beatriz
  • Stanley, Sabrina
  • Davidson, Alan

Abstract

The present disclosure provides compositions and methods for introducing or enhancing Aca activity in prokaryotic cells. The provided compositions and methods can be used to inhibit Acr activity in prokaryotic cells, thereby enhancing endogenous or exogenous CRISPR-Cas activity. Cells, polynucleotides, plasmids, phage, and other elements for practicing the present methods are also provided.

IPC Classes  ?

  • G01C 19/34 - Rotary gyroscopes for indicating a direction in the horizontal plane, e.g. directional gyroscopes

82.

REAL-TIME METHODS TO ENABLE PRECISION-GUIDED CPR TO IMPROVE NEUROLOGICAL OUTCOME AND PREDICT BRAIN DAMAGE

      
Application Number US2020035440
Publication Number 2020/243658
Status In Force
Filing Date 2020-05-29
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Wilson, Robert, H.
  • Crouzet, Christian
  • Akbari, Yama
  • Choi, Bernard
  • Tromberg, Bruce, J.

Abstract

A multimodal optical imaging platform is used to obtain cerebral perfusion- metabolism mismatch metrics for rapid assessment of acute brain injury, ongoing (real- time) feedback to optimize cardiopulmonary resuscitation to improve neurological outcome, and rapid prognosis of recovery. Light of several wavelengths and types is delivered to the tissue, which is then absorbed and scattered by tissue components such as blood and cellular components. Some of this light scatters back to the surface, where it is captured by a detector. The resulting data are processed to obtain blood flow and oxygenation parameters, as well as tissue scattering. These parameters are then combined to calculate metabolism and flow-metabolism coupling/decoupling metrics, which are used to determine ischemic damage, ongoing need for optimal blood flow and oxygenation, and to predict cerebral recovery in patients with acute brain injury during and immediately after cardiac arrest, stroke, traumatic brain injury, etc.

IPC Classes  ?

  • A61H 31/00 - Artificial respiration or heart stimulation, e.g. heart massage
  • A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves

83.

SWITCHNG INTERVAL MODULATION WITH PULSE ENCODED TRANSITIONS

      
Application Number US2020032910
Publication Number 2020/242778
Status In Force
Filing Date 2020-05-14
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Hill, Cameron
  • Buckwalter, James F.

Abstract

A method for switching interval modulation includes modulating an RF input data signal while generating and inserting additional pulses in transitions of the data signal. The additional pulses are structured to shift transition noise into higher order harmonics. Higher order harmonics are easily filtered. The generating is conducted in the digital domain. The additional pulses can be used to simplify the transmit chain through optical modulators and improve the signal integrity over long distances, can be applied at the output of a transmitter to filter power amplifier distortion, and can be appplied to non-linear RF over fiber for a distributed MIMO system.

IPC Classes  ?

  • H04L 25/49 - Transmitting circuits; Receiving circuits using three or more amplitude levels
  • H03C 3/09 - Modifications of modulator for regulating the mean frequency

84.

COMPOSITIONS AND METHODS FOR TREATING CANCER

      
Application Number US2020034137
Publication Number 2020/242910
Status In Force
Filing Date 2020-05-22
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OFCALIFORNIA (USA)
Inventor
  • Chute, John, P.
  • Sasine, Joshua

Abstract

Disclosed herein are methods of treating certain cancers (e.g., myeloma) with inhibitors of ephrin-Eph signaling. Also disclosed herein are compositions comprising inhibitors of ephrin-Eph signaling.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61K 31/00 - Medicinal preparations containing organic active ingredients

85.

TH1-POLARIZING ADJUVANTS FOR ENHANCING IMMUNOGENICITY OF HIV ANTIGENS

      
Application Number US2020034688
Publication Number 2020/243166
Status In Force
Filing Date 2020-05-27
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Iyer, Smita S.

Abstract

The present disclosure provides methods and compositions for enhancing an immune response in a subject undergoing HIV vaccination. In particular, the present disclosure provides adjuvants and methods for increased Th1 polarization of T cells in a subject in order to enhance the immune reaction against an HIV antigen.

IPC Classes  ?

  • A61K 39/12 - Viral antigens
  • A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
  • A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

86.

III-NITRIDE-BASED VERTICAL CAVITY SURFACE EMITTING LASER (VCSEL) CONFIGURATIONS

      
Application Number US2020034955
Publication Number 2020/243330
Status In Force
Filing Date 2020-05-28
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Kearns, Jared
  • Cohen, Daniel A.
  • Back, Joonho
  • Palmquist, Nathan
  • Margalith, Tal
  • Denbaars, Steven P.
  • Nakamura, Shuji

Abstract

Vertical Cavity Surface Emitting Laser (VCSEL) configurations are disclosed. In a first example, the VCSEL includes a III-Nitride active region between a p-type III-Nitride layer and an n-type III-Nitride layer; and a curved mirror on or above the p-type III-Nitride layer. The curved mirror can be formed in a III-Nitride layer or a Transparent Oxide (TO) material and enables the formation of a long VCSEL cavity that improves VCSEL lifetime, VCSEL output power, VCSEL power efficiency and VCSEL reliability. In a second example, the VCSEL has an active region with a high indium content. In a third example, the VCSEL is transparent.

IPC Classes  ?

  • H01S 5/183 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only vertical cavities, e.g. vertical cavity surface-emitting lasers [VCSEL]

87.

METHODS, SYSTEMS, AND DEVICES FOR TRUSTED EXECUTION ENVIRONMENTS AND SECURE DATA PROCESSING AND STORAGE ENVIRONMENTS

      
Application Number US2020034994
Publication Number 2020/243362
Status In Force
Filing Date 2020-05-28
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Peisert, Sean

Abstract

Disclosed herein are methods, systems, and devices for implementing trusted execution environments in the context of data security and data storage. Systems may include a login node comprising one or more processors configured to receive a request from a user, and a secure access port communicatively coupled to the login node and configured to process the request in accordance with one or more data access policies. Systems may further include a secure processing device communicatively coupled to the secure access port and comprising an encrypted portion configured to implement one or more data processing operations associated with the request. The systems may also include an encrypted data repository communicatively coupled to the secure processing device, the encrypted data repository comprising one or more storage devices, and being configured to encrypt and store data in the one or more storage devices.

IPC Classes  ?

  • G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
  • G06F 21/72 - Protecting specific internal or peripheral components, in which the protection of a component leads to protection of the entire computer to assure secure computing or processing of information in cryptographic circuits

88.

LOW BAND GAP GRAPHENE NANORIBBON ELECTRONIC DEVICES

      
Application Number US2020035128
Publication Number 2020/243435
Status In Force
Filing Date 2020-05-29
Publication Date 2020-12-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Fischer, Felix, Raoul
  • Bokor, Jeffrey
  • Mutlu, Zafer
  • Llinas, Juan, Pablo
  • Mccurdy, Ryan, David
  • Veber, Gregory, Clinton
  • Koenigs, Dharati, Joshi

Abstract

Various chemical structures of precursors for armchair graphene nanoribbons (AGNRs) are disclosed, along with a method of manufacturing.

IPC Classes  ?

89.

BIOMETRIC IDENTIFICATION THROUGH INTRA-BODY COMMUNICATION

      
Application Number US2020033060
Publication Number 2020/236553
Status In Force
Filing Date 2020-05-15
Publication Date 2020-11-26
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Khorshid, Ahmed Eissa Fathy
  • Eltawil, Ahmed Mohamed
  • Piqueras Jover, Roger

Abstract

Biometric identification through intra-body communication is described. In one embodiment, a system for biometric identification includes a biometric transmitter device and a biometric receiver device. The biometric transmitter device includes at least one transmit electrode for contact with skin of an individual at a first location on the skin, and the biometric transmitter device is configured to transmit a signal through the transmit electrode and the skin. The biometric receiver device includes at least one receive electrode for contact with the skin of the individual at a second location on the skin, and the biometric receiver is configured to receive the signal through the receive electrode for biometric authentication of the individual.

IPC Classes  ?

  • G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
  • G06F 7/04 - Identity comparison, i.e. for like or unlike values
  • H04L 29/06 - Communication control; Communication processing characterised by a protocol

90.

PERCUTANEOUS MEDICAL DEVICE DELIVERY SYSTEM

      
Application Number US2020033466
Publication Number 2020/236750
Status In Force
Filing Date 2020-05-18
Publication Date 2020-11-26
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Kheradvar, Arash
  • Kelley, Gregory, S.

Abstract

A medical device delivery system including a delivery sheath that includes an internal lumen, and a plurality of delivery arms contained within the internal lumen of the delivery sheath and extending along a longitudinal axis of the internal lumen of the delivery sheath, wherein distal ends of the delivery arms include fasteners configured to engage with a basal structure of a medical device and a apical structure of the medical device, wherein the delivery arms are attached to delivery arm controls that are configured to advance the delivery arms and the medical device attached thereto out from a distal end of the delivery sheath, and removable release wires or release lines configured to engage with the fasteners to hold the basal structure and the apical structure in place at the fasteners. Also disclosed are methods of delivering a medical device to a subject including inserting a distal end of the medical device delivery system through an incision in the skin of subject, and deploying a medical device engaged with the delivery arms of the medical delivery system to within the body of the subject.

IPC Classes  ?

  • A61M 1/12 - Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps implantable into the body
  • A61H 31/00 - Artificial respiration or heart stimulation, e.g. heart massage
  • A61M 1/10 - Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps
  • A61N 1/362 - Heart stimulators

91.

ZIKA VIRUS CONSTRUCTS AND THERAPEUTIC COMPOSITIONS THEREOF

      
Application Number US2020033705
Publication Number 2020/236874
Status In Force
Filing Date 2020-05-20
Publication Date 2020-11-26
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Arumugaswami, Vaithilingaraja
  • Garcia, Jr., Gustavo
  • Nathanson, David, A.
  • Sun, Ren

Abstract

Disclosed herein are Zika virus constructs and methods of using Zika virus constructs and Zika viruses to treat subjects in need thereof.

IPC Classes  ?

  • A61K 39/12 - Viral antigens
  • C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus

92.

COMPOSITIONS AND METHODS FOR CELLULAR DELIVERY

      
Application Number US2020033730
Publication Number 2020/236894
Status In Force
Filing Date 2020-05-20
Publication Date 2020-11-26
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Sletten, Ellen M.
  • Estabrook, Daniel A.
  • Chapman, John O.

Abstract

Disclosed herein are amphiphilic polymers and hierarchical structures (e.g., emulsions) comprising said polymer. Also disclosed herein are methods of using the polymers and hierarchical structure disclosed herein.

IPC Classes  ?

  • C08F 20/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
  • C08F 22/10 - Esters
  • C08F 22/38 - Amides
  • C08F 16/06 - Polyvinyl alcohol
  • C08F 16/18 - Acyclic compounds
  • C08L 29/04 - Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
  • C08L 33/08 - Homopolymers or copolymers of acrylic acid esters
  • C08L 71/02 - Polyalkylene oxides

93.

METHODS FOR IMPROVING THE TISSUE SEALING PROPERTIES OF HYDROGELS AND THE USE THEREOF

      
Application Number US2020033775
Publication Number 2020/236917
Status In Force
Filing Date 2020-05-20
Publication Date 2020-11-26
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Sheikhi, Amir
  • Annabi, Nasim
  • Khademhosseini, Alireza

Abstract

Naturally-derived biopolymers, such as proteins and polysaccharides are a promising platform for developing materials that readily adhere to tissues upon chemical crosslinking and provide a regenerative microenvironment. Here, we show that the sealing properties of a model biopoiymer sealant, gelatin methacryloyl (GelMA), can be precisely controlled by adding a small amount of a synthetic polymer with identically reactive moieties, i.e., poly (ethylene glycol) diacrylate (PEG DA). For example, we have discovered a more than 300% improvement in tissue sealing capability of 20% (w/v) GelMA adhesive can be obtained by adding only 2- 3% (v/v) PEGDA, without any significant effect on the sealant degradation time scale. These hybrid hydrogels with improved sealing properties are suitable for sealing stretchable organs, such as bladder, as well as for the anastomosis of tubular tissues/organs.

IPC Classes  ?

  • A61L 27/52 - Hydrogels or hydrocolloids
  • A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
  • A61L 27/20 - Polysaccharides
  • A61L 27/22 - Polypeptides or derivatives thereof
  • C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)

94.

KRAS G12C INHIBITORS AND USES THEREOF

      
Application Number US2020033816
Publication Number 2020/236940
Status In Force
Filing Date 2020-05-20
Publication Date 2020-11-26
Owner
  • CALIFORNIA INSTITUTE OF TECHNOLOGY (USA)
  • 1200 PHARMA LLC (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Hilf, Justin, A.
  • Rose, Tristin, E.
  • Bartberger, Michael, D.
  • O'Boyle, Brendan, M.
  • Reeves, Corey, M.
  • Loson, Oliver, C.
  • Stoltz, Brian, M.
  • Mcdermott, Martina, S.
  • O'Brien, Neil, A.
  • Slamon, Dennis

Abstract

The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.

IPC Classes  ?

  • C07D 487/10 - Spiro-condensed systems
  • C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D 495/10 - Spiro-condensed systems
  • C07D 498/10 - Spiro-condensed systems
  • C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61K 31/527 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
  • A61P 35/00 - Antineoplastic agents

95.

APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF

      
Application Number US2020033836
Publication Number 2020/236952
Status In Force
Filing Date 2020-05-20
Publication Date 2020-11-26
Owner
  • OHIO STATE INNOVATION FOUNDATION (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Susin Pires, Ivan
  • Palmer, Andre
  • Cabrales Arevalo, Pedro J.

Abstract

Provided herein are apohemoglobin-haptoglobin complexes as well as apohemoglobin-haptoglobin complexes comprising an active agent coordinated thereto. Methods of using these compositions are also described.

IPC Classes  ?

  • A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
  • A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
  • A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
  • A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • A61P 37/02 - Immunomodulators

96.

VACCINE COMPOSITIONS FOR CLOSTRIDIUM DIFFICILE

      
Application Number US2020034070
Publication Number 2020/237090
Status In Force
Filing Date 2020-05-21
Publication Date 2020-11-26
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Jin, Rongsheng
  • Felgner, Philip
  • Chen, Peng

Abstract

Methods and compositions for treating or preventing C. difficile infection (CDI) through TcdB or Ted A holotoxins. The compositions feature immunogens or binding agents, such as antibodies, nanobodies (VHHs), single-domain antibodies (sdAbs), etc., based on one or a combination of neutralizing epitopes of TcdB or TcdA. Where immunogens inhibit the conformational changes necessary for pore formation by TcdB at an endosomal pH. Additionally, immunogens inhibit the movement of the scissile bond into the CPD cleavage side and a proper orientation of GTD relative to CPD, thus inhibiting cleavage of the GTD, which is required to activate the toxin. The present invention also describes vaccines for treatment of CDI, e.g., vaccines that target TcdB or TccLA.

IPC Classes  ?

  • A61K 39/08 - Clostridium, e.g. Clostridium tetani
  • C07K 14/33 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
  • C12R 1/145 - Clostridium

97.

MMP-9 ANTIBODIES AND METHODS OF USE THEREOF

      
Application Number US2020034076
Publication Number 2020/237092
Status In Force
Filing Date 2020-05-21
Publication Date 2020-11-26
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • DUKE UNIVERSITY (USA)
Inventor
  • Ge, Xin
  • Lopez, Tyler
  • Ji, Ru-Rong

Abstract

Certain embodiments provide an isolated anti-matrix metalloproteinase-9 (MMP-9) antibody or fragment thereof, as well as methods of use thereof.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

98.

AUTOMATED ULTRA-COMPACT MICRODROPLET RADIOSYNTHESIZER

      
Application Number US2020034336
Publication Number 2020/237195
Status In Force
Filing Date 2020-05-22
Publication Date 2020-11-26
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Van Dam, Michael R.
  • Wang, Jia

Abstract

A chemical synthesis platform based on a particularly simple chip is described herein, where reactions take place atop a hydrophobic substrate patterned with a circular hydrophilic liquid trap. The overall supporting hardware (heater, rotating carousel of reagent dispensers, etc.) can be packaged into a very compact format (about the size of a coffee cup). We demonstrate the consistent synthesis of [18F]fallypride with high yield, and show that protocols optimized using a high-throughput optimization platform we have developed can be readily translated to this device with no changes or reoptimization.

IPC Classes  ?

  • A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
  • A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
  • B01L 3/02 - Burettes; Pipettes
  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
  • H01L 23/46 - Arrangements for cooling, heating, ventilating or temperature compensation involving the transfer of heat by flowing fluids
  • G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices

99.

TRACELESS LINKER AND METHODS OF USE THEREOF

      
Application Number US2020032916
Publication Number 2020/236521
Status In Force
Filing Date 2020-05-14
Publication Date 2020-11-26
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • He, Maomao
  • Murthy, Niren
  • Li, Jie
  • Han, Hesong

Abstract

The present disclosure provides a linker that includes functional groups for attaching molecules of interest, where the linker includes a thiol ethyl carbonate group and a 1,6-elimination group that undergoes cleavage under physiological reducing conditions, releasing the molecules of interest. The present disclosure provides compounds comprising a first and a second molecule of interest linked by a linker of the present disclosure. The present disclosure provides methods of using a compound of the present disclosure to deliver a molecule of interest.

IPC Classes  ?

  • A61K 38/46 - Hydrolases (3)
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 9/22 - Ribonucleases

100.

MITOCHONDRIAL RESPIROMETRY IN FROZEN SPECIMENS

      
Application Number US2020033112
Publication Number 2020/236580
Status In Force
Filing Date 2020-05-15
Publication Date 2020-11-26
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Shirihai, Orian S.
  • Benador, Ilan Yaacov
  • Acin-Perez, Rebeca
  • Stiles, Linsey

Abstract

Mitochondrial respirometry is used to study mitochondrial functionality in healthy tissues as well as mitochondrial diseases or diseases having a link to mitochondrial function such as diabetes mellitus type 2, obesity and cancer. However, barriers to studying energy metabolism are high due to the limitations of conventional technologies which require the analysis of living or freshly isolated biological specimens. The invention disclosed herein provides a new technology to assess cellular energy production capacity in previously frozen biological specimens.

IPC Classes  ?

  • A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
  • A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
  1     2     3     ...     81        Next Page